HCPCS Code J1050: Medroxyprogesterone acetate injection billing guide

Key Takeaways

HCPCS Code J1050 describes injection of medroxyprogesterone acetate at 1 mg per billable unit, covering Depo-Provera and Depo-subQ Provera 104

The standard 150 mg IM Depo-Provera dose requires 150 units of J1050 on the claim; billing fewer units is the most common denial trigger

Always pair J1050 with CPT 96372 for the administration service, and include the NDC on Medicaid claims or face automatic rejection

Pabau’s claims management software stores HCPCS drug codes, calculates units automatically, and flags missing NDC or modifier fields before submission

HCPCS Code J1050 is billed per 1 mg of medroxyprogesterone acetate, covering both the intramuscular Depo-Provera and subcutaneous Depo-subQ Provera 104 formulations. A standard 150 mg intramuscular dose is billed as 150 units, and the 104 mg subcutaneous dose is billed as 104 units — getting that unit count wrong is the most common cause of J1050 claim denials.

This guide covers unit calculation, administration code pairing, OB/GYN practice billing workflows, NDC reporting, modifiers, Medicare reimbursement, and common denial patterns.

What is HCPCS Code J1050?

HCPCS Code J1050 is a Level II Healthcare Common Procedure Coding System code used to bill injectable medroxyprogesterone acetate at 1 mg per unit. The official long descriptor is: Injection, medroxyprogesterone acetate, 1 mg. It falls under the J-code series, which covers drugs administered by a provider in an office or outpatient setting and billed separately from the administration service.

Per CMS’s HCPCS overview, Level II codes are maintained by the CMS HCPCS Workgroup and updated annually.

The code applies to two branded formulations of medroxyprogesterone acetate (MPA): Depo-Provera 150 mg/mL administered intramuscularly, and Depo-subQ Provera 104 mg/0.65 mL administered subcutaneously. The descriptor doesn’t specify route, so both formulations are billed under J1050 — 150 units for the intramuscular dose, 104 units for the subcutaneous dose.

Therapeutically, medroxyprogesterone acetate serves two distinct clinical contexts: contraception, the most common outpatient indication, and oncology, primarily endometrial cancer treatment. The documented clinical indication must align with the ICD-10 diagnosis code submitted on the claim. Oncology administrations sometimes pair J1050 with the antiemetic palonosetron, billed under HCPCS Code J2469, when chemotherapy-associated nausea applies.

J1050 code details at a glance

How to calculate billing units for J1050

J1050 billing units map directly to milligrams administered: one unit equals 1 mg of medroxyprogesterone acetate. For the standard intramuscular Depo-Provera dose of 150 mg, bill 150 units. For the subcutaneous Depo-subQ Provera 104 dose, bill 104 units.

The most common billing error here is submitting 1 unit instead of 150, treating J1050 like a per-encounter code rather than a per-milligram code. Practices using claims management software with a drug code library can configure J1050 to auto-populate 150 units when a Depo-Provera service is documented, eliminating this manual step.

For sexual health clinics and family planning practices administering Depo-Provera at high volume, automating unit calculation is the single fastest path to fewer claim rejections.

Paired administration code: CPT 96372

J1050 covers the drug cost only. The injection service itself is billed separately using CPT 96372, the code for a therapeutic, prophylactic, or diagnostic injection given subcutaneously or intramuscularly. Both codes appear on the same claim line, with a single unit of CPT 96372 alongside the appropriate unit count of J1050.

Place of service matters here. The combination of J1050 + CPT 96372 is appropriate for POS 11 (office) and most outpatient settings. Some payers, particularly Medicaid managed care plans, bundle CPT 96372 into the drug administration and will not reimburse it separately.

Verify payer-specific bundling rules before submitting. For reproductive health billing contexts, always confirm whether the plan applies NCCI edits to the J-code and administration code pair.

ICD-10 diagnosis codes to pair with J1050

Medical necessity for J1050 claims depends on pairing the correct ICD-10-CM diagnosis code. The most common codes submitted with J1050 are shown below. The documented indication must match the coded diagnosis; contraceptive and oncologic claims require different codes.

Practices administering J1050 during routine well-woman visits often bill cervical cancer screening under HCPCS Code G0145 in the same encounter, so both code sets should stay current in the charge master.

Z30.42 is the standard diagnosis for family planning encounters. Using a less specific code when Z30.42 is clearly applicable is a coding accuracy issue that can trigger audit findings. Practices managing HIPAA-compliant patient records should ensure the clinical note documents the indication explicitly so the coder can assign the correct diagnosis without guessing.

NDC reporting requirements for HCPCS Code J1050

Medicaid requires a National Drug Code (NDC) on every J-code drug claim, including J1050. Missing the NDC on a Medicaid claim results in automatic rejection. The NDC must be reported in the 5-4-2 format (labeler-product-package) and should reflect the specific vial or package dispensed, not a generic placeholder.

Two formulations of medroxyprogesterone acetate are commonly billed under J1050. NDC numbers can vary by lot and manufacturer, so always verify against the current FDA drug labeling rather than relying on stored values that may be outdated. For prescription management workflows, cross-referencing the NDC at the time of dispensing is the most reliable approach.

Medicare Part B does not mandate NDC reporting on claims at the federal level, but some Medicare Advantage plans may require it.

J1050 modifiers: JW, JZ, and others

Modifier JW identifies the discarded or wasted portion of a single-use drug vial. When a provider administers less than the full vial content of medroxyprogesterone acetate, modifier JW is appended to a second J1050 line to report the discarded amount. This allows full vial reimbursement while documenting that not all drug was administered.

Modifier JZ, effective for dates of service on or after January 1, 2023, is used when there is no discarded drug. It serves as the affirmative attestation that the entire vial was administered. CMS requires either JW or JZ on single-dose drug claims; submitting neither can trigger claim edits.

Verify current effective-date guidance via the CMS Physician Fee Schedule search tool before asserting payer-specific modifier rules, as policy can change annually.

Other modifiers may also apply. Modifier 59 (distinct procedural service) applies when J1050 is billed on the same date as another drug. Modifier 76 (repeat procedure) applies for same-day repeat administration.

Medicare and Medicaid fee schedule for J1050

Medicare Part B reimburses J1050 under the Average Sales Price (ASP) methodology at ASP + 6% per unit, paid to the administering provider. Because ASP changes quarterly, the per-unit rate for J1050 fluctuates. For the 150-unit standard dose, the total reimbursement is the per-unit rate multiplied by 150.

Always check the current quarterly ASP file on CMS.gov rather than using prior-quarter figures. Using stale rates in your fee schedule leads to systematic underbilling or patient balance errors.

Medicaid reimbursement for J1050 varies by state. Most states cover medroxyprogesterone acetate injections for family planning under Medicaid, and many states operate a family planning carve-out program that covers J1050 with no prior authorization (PA) required.

Commercial payers vary significantly: some require PA for Depo-Provera under pharmacy benefits, others cover it under the medical benefit without PA. Never generalize PA requirements across payers; verify plan-specific coverage before administering. For reproductive health and OB/GYN practice billing, maintaining an up-to-date payer matrix for J1050 PA requirements is standard operating procedure.

Is J1055 ever the right code instead of J1050?

No. J1055 is not a current billing option. CMS deleted J1055, along with J1051 and J1056, effective January 1, 2013, after terminating the codes on December 31, 2012. J1050, the per-1-mg code, replaced all three.

Before deletion, J1055’s descriptor was Injection, medroxyprogesterone acetate for contraceptive use, 150 mg — the 150 mg intramuscular contraceptive product, not the 104 mg subcutaneous Depo-subQ Provera some coders assume it covered. If J1055 still appears in an old charge master or payer fee schedule, treat it as a legacy reference only.

J1050 is the only active code for either formulation: bill 150 units for the 150 mg intramuscular dose and 104 units for the 104 mg subcutaneous Depo-subQ Provera dose. For compounded or non-standard medroxyprogesterone acetate formulations that don’t match either product, some payers may require the unclassified drug code J3490 instead — confirm with the payer before submitting.

Common billing errors for HCPCS Code J1050 and how to avoid them

Several recurring denial patterns appear on J1050 claims. Recognizing them before submission is faster than working a denial.

• Wrong unit count: Submitting 1 unit instead of 150 for the standard IM dose. Fix: configure the drug code in your billing system to auto-populate 150 units for Depo-Provera 150 mg orders.
• Missing NDC on Medicaid claims: Medicaid auto-rejects J-code claims without a valid NDC in 5-4-2 format. Fix: make NDC entry a required field in the charge capture workflow for all injectable drug services.
• No administration code: Submitting J1050 without CPT 96372 means the drug is paid but the injection service is not. Fix: create a linked billing pair so both codes populate together. For guidance on linking drug and administration codes, refer to AAPC’s HCPCS code reference.
• Missing or wrong modifier: Omitting JW or JZ on single-dose vials triggers CMS edits. Fix: add a modifier decision prompt to the charge entry screen when a J-code is selected.
• Wrong place of service: POS 11 (office) is standard. Using an incorrect POS code for an outpatient setting changes the expected fee schedule and can cause a mismatch rejection.
• Using Q0090 on current claims: Q0090 was retired when J1050 took its place. Any claim submitted with Q0090 will be rejected. This crosswalk matters most for practices using older charge master files that have not been updated.

How practice management software can streamline J1050 billing

Most J1050 denials trace back to workflow breakdowns rather than coding knowledge: a unit count not updated when a new formulation was stocked, an NDC field skipped because it was optional in the software, or a modifier forgotten at end-of-day batch entry.

Practice management software with built-in drug code logic closes these breakdowns at the point of care rather than during denial management.

Practice management software like Pabau supports injectable drug billing workflows through its claims management tools, including the ability to configure HCPCS J-code entries with default unit values and required fields for modifiers and NDC.

For OB/GYN and women’s health practices that administer Depo-Provera regularly, this configuration means billers spend time reviewing claims instead of re-entering data that the clinical documentation already contains.

Practices using digital intake forms and clinical documentation can link the documented dose directly to the billing entry, reducing the transcription errors that create unit-count mismatches. For practices exploring other procedure code billing setups, the same automated field logic applies across J-code and CPT-code workflows.

Reduce J1050 claim rejections before they happen

Pabau's claims management software lets you configure HCPCS drug codes with auto-populated unit values, required NDC fields, and modifier prompts. Fewer denials. Less time on appeals.

Book a demo

Conclusion

HCPCS Code J1050 is one of the higher-volume J-codes in family planning and OB/GYN billing, and its denial rate is largely preventable. Three fields drive most of the problems: unit count, NDC, and modifier. Get those right consistently, pair the code correctly with CPT 96372 and the appropriate Z30.42 diagnosis, and the claim processes cleanly.

For practices looking to move from manual drug code entry to an automated workflow, see how Pabau handles injectable drug billing at the practice level. HIPAA-compliant documentation workflows that link clinical notes to charge capture are the foundation. To see the full claims workflow in action, book a demo.

Continue your research

Billing another injectable drug HCPCS code? HCPCS code J2795 covers ropivacaine hydrochloride injection billing, including unit calculation and administration pairing.

Need the supply-side billing code for the injection itself? HCPCS Code A4208 covers the sterile syringe with needle used to administer injectable drugs like medroxyprogesterone acetate.

Working through other HCPCS billing guides? HCPCS Code C1733 breaks down electrophysiology catheter billing with the same unit and modifier logic covered here.

Frequently asked questions